Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089260 | 0.97 | CYP2C19 (0.38) | FFAR3AKR1C1OPRM1OPRL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL6601346 | 0.97 | FFAR3 (0.36) | FFAR3AKR1C1OPRM1OPRL1CYP2C19 | |
| SCHEMBL22533638 | 0.95 | FFAR3 (0.38) | FFAR3AKR1C1OPRM1OPRL1CYP2C19 | |
| SCHEMBL643056 | 0.89 | — | — | |
| SCHEMBL23832502 | 0.80 | CYP2C19 (0.37) | FFAR3AKR1C1CYP2C19LMNAMEN1 | |
| SCHEMBL17144836 | 0.78 | OPRM1 (0.39) | FFAR3OPRM1OPRL1FABP4KMT2A | |
| SCHEMBL20599700 | 0.78 | OPRM1 (0.40) | FFAR3OPRM1OPRL1CYP2C19FABP4 | |
| SCHEMBL12861247 | 0.77 | LMNA (0.35) | OPRM1OPRL1LMNAMEN1POLB | |
| SCHEMBL2832684 | 0.77 | LMNA (0.33) | LMNAMEN1POLBKMT2A | |
| SCHEMBL1583413 | 0.77 | FFAR3 (0.32) | FFAR3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | WANG JIANMIN | 2010-07-22 | — | — | US | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3411371-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | Pfizer Inc (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | FFAR3 720/4885AKR1C1 94/4885OPRM1 3123/4885 |
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | NGLY1, TEK, TEKT1 | FFAR3 2962/4885AKR1C1 4214/4885OPRM1 4012/4885 |
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | REN, ACE, AGTR1 | FFAR3 148/4885AKR1C1 65/4885OPRM1 1136/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | FFAR3 2962/4885AKR1C1 4214/4885OPRM1 4012/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | FFAR3 720/4885AKR1C1 94/4885OPRM1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.